Astec Lifesciences Share Price

NSE
ASTEC •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or Open Demat Account for live prices.
Start SIP in Astec Lifesciences
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
New 52W Low in past week
-31.4
TTM PE Ratio
Negative PE TTM
-12
Price to Book Ratio
Above industry Median
4.9
Dividend yield 1yr %
0
TTM PEG Ratio
PEG TTM is less than 1
0.1

Astec Lifesciences Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Astec Lifesciences Quarterly Revenue

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
93.86 Cr
98.55 Cr
69.37 Cr
153.75 Cr
50.79 Cr

Astec Lifesciences Yearly Revenue

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
463.82 Cr
641.23 Cr
687.03 Cr
562.79 Cr
534.54 Cr

Astec Lifesciences Quarterly Net Profit/Loss

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
-40.37 Cr
-38.55 Cr
-39.72 Cr
-0.96 Cr
-24.33 Cr

Astec Lifesciences Yearly Net Profit/Loss

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
-46.89 Cr
25.59 Cr
89.88 Cr
65.07 Cr
47.53 Cr
Astec Lifesciences Result Highlights
  • Astec Lifesciences Ltd reported a 4.7% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 85.2%.

  • Its expenses for the quarter were down by 13.1% QoQ and up 44.1% YoY.

  • The net profit increased 4.7% QoQ and increased 66.0% YoY.

  • The earnings per share (EPS) of Astec Lifesciences Ltd declined at 20.6 during Q3FY25.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Astec Lifesciences shareholding Pattern

Promoter
66.8%
Foreign Institutions
1.2%
Mutual Funds
4%
Domestic Institutions
5.4%
Public
26.6%
Promoter
66.8%
Foreign Institutions
0.5%
Mutual Funds
4%
Domestic Institutions
4.5%
Public
28.2%
Promoter
66.8%
Foreign Institutions
1%
Mutual Funds
3%
Domestic Institutions
3.4%
Public
28.8%
Promoter
66.8%
Foreign Institutions
1.2%
Mutual Funds
7.8%
Domestic Institutions
7.9%
Public
24.1%
Promoter
66.8%
Foreign Institutions
1.3%
Mutual Funds
8.8%
Domestic Institutions
9.7%
Public
22.2%
Promoter
66.8%
Foreign Institutions
1.3%
Mutual Funds
9.2%
Domestic Institutions
10.2%
Public
21.7%

Astec Lifesciences Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
16
5Day EMA
763.40
10Day EMA
806.10
12Day EMA
820.80
20Day EMA
867.90
26Day EMA
894.00
50Day EMA
958.60
100Day EMA
1,025.90
200Day EMA
1,090.60
5Day SMA
744.30
10Day SMA
817.70
20Day SMA
892.40
30Day SMA
932.30
50Day SMA
993.90
100Day SMA
1,037.00
150Day SMA
1,097.20
200Day SMA
1,134.60
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
17932 Rs
29382 Rs
Week Rs
39315 Rs
77955 Rs
Month Rs
18372 Rs
38954 Rs
Resistance & Support
746.72
Pivot
Resistance
First Resistance
769.63
Second Resistance
809.92
Third Resistance
832.83
Support
First Support
706.43
Second support
683.52
Third Support
643.23
Relative Strength Index
28.71
Money Flow Index
16.61
MACD
-73.12
MACD Signal
-57.65
Average True Range
60.10
Average Directional Index
42.48
Rate of Change (21)
-24.24
Rate of Change (125)
-40.28

Astec Lifesciences Company background

Founded in: 1994
Astec LifeSciences Ltd is a producer of agrochemicals and pharmaceutical intermediates. The company manufactures a wide range of Agrochemical active ingredients and pharmaceutical intermediates. They are having manufacturing facilities located at two locations in Maharashtra, India comprising of three units viz. one unit at Dombivli, Maharashtra and two units at Mahad, Maharashtra (Unit 1 and Unit 2). They are exporting their products to East Asia, Europe, Middle East, and USA.The business of the company comprises of the two major segments, namely Agrochemicals and Pharmaceuticals. Under the Agrochemical segment, the company manufactures active ingredients, intermediates and formulations. Active ingredients are sold to crop protection formulators. Intermediates are supplied to technical grade product manufacturers. Formulations are sold in bulk quantities to companies engaged in retail marketing. Under the Pharmaceutical segment, the company carries out manufacturing of intermediates which are supplied to Active Pharma Ingredients (API) manufacturers.Astec LifeSciences Ltd was incorporated on January 25, 1994 as a private limited company with the name Urshila Traders Pvt Ltd. The company was originally promoted by Reena Bagai and Avita Fernandes. Their shareholding was purchased by Ashok Hiremath and Pratap Garud on February 11, 1994. In August 19, 1994, the name of the company was changed from Urshila Traders Pvt Ltd to Astec Chemicals Pvt Ltd.In August 1994, the company started their first manufacturing unit by acquiring a sick unit in Dombivli, Maharashtra having an installed capacity of 120 MT for the manufacture of Dicap, a pharmaceutical intermediate. In May 2001, they were awarded ISO 9002 Certification by International Standards Certification Pty Limited, Australia.In February 18, 2002, the company entered into an agreement with Behram Chemicals Pvt Ltd with a view to expand their operations for using and operating their manufacturing facilities located at Mahad in Maharashtra. Behram Chemicals Pvt Ltd was engaged in manufacture of chemicals and pesticides with installed capacity of 130 MT.During the year 200304, the company expanded the total installed capacity of their units (Dombivli and Mahad) from 250 MT to 500 MT. In the year 2004, they acquired a plot of land located at Mahad, Maharashtra. In May 2005, they set up a new manufacturing facility as an Export Oriented Unit (as Unit 2), which is adjacent to Unit 1 with an installed capacity of 1000 MT. With the commissioning of Unit 2, the companys total installed capacity increased to 1500 MT.In March 2006, the name of the company was changed from Astec Chemicals Pvt Ltd to Astec LifeSciences Pvt Ltd. In April 2006, the company was converted into public limited company and the name was changed to Astec LifeSciences Ltd. During the year 200607, the company further expanded their total capacities to 2000 MT. In January 2007, they established Astec Europe in Tournai, Belgium.During the year 200708, the company increased the production capacity of Agro Pharma Intermediates by 500 MT to 2500 MT In April 2007, Behram Chemicals Pvt Ltd became the subsidiary of the company by the acquisition of 65.63% equity by the company vide Share Purchase Agreement.During the year 200809, the company increased the production capacity of Agro Pharma Intermediates by 300 MT to 2800 MT. They established a relationship with a major multinational for supply of one of our products into the global supply chain.During the year 200910, the company increased the production capacity of Agro Pharma Intermediates by 350 MT to 3150 MT. They also introduced new measures to improve EHS performance. In December 2009, the company has bagged orders worth Rs 7 crore from Syngenta India and Nufarm, which are amongst the worlds top ten largest agrochemical manufacturing companies. In June 2010, the company entered into a long term mutually exclusive confidential contract to supply an herbicide to a multinational agrochemical major. In August 2010, the company acquired land in MIDC Mahad area admeasuring 40000 sq mtrs with a view to set up additional manufacturing facilities on the new site.In August 27, 2010, the companys Chairman Managing Director, Ashok V Hiremath was awarded Prestigious Business Excellence Award by the IndoThai Entrepreneurs Summit Bangkok, Thailand for his outstanding contribution towards progress and development of Indian Economy and Society.The Company incorporated a 100% wholly owned subsidiary, Astec CropCare Pvt. Ltd. to start the business of trading in agrochemicals and pesticides formulations to sell products. It made investments to increase the capacity of its manufacturing facility and to improvc the quality of products in Mahad. Work was started on construction of new 40000 sq m site at Mahad in Apr 11. During the year 201213, the Company has setup a new subsidiary namely, Comercializadora Agricola Agroastrachem Cia Ltda in Bagota, Columbia.During period 201516, Godrej Agrovet Limited acquired 45.29% of the Equity Share Capital of the Company from its exPromoters through an offmarket transaction on 12th October, 2015 and consequently, the Company became a subsidiary of Godrej Agrovet Limited with effect from 6th November, 2015. Godrej Agrovet Limited got listed on the Stock Exchanges, viz., BSE Limited and National Stock Exchange of India Limited on 16th October, 2017.During Financial Year 202021, Company sold off its entire equity stake in Astec Europe Sprl (a 50.10% subsidiary of Company in Belgium, Europe), in terms of a Share Purchase Agreement executed on 31st August 2020. Accordingly, Astec Europe Sprl ceased to be a subsidiary of Company with effect from 1st September, 2020.During the Financial Year 202122, Company also commissioned its new herbicide plant and completed first batch of CMO product. It commercialized two new CMO products and a new production process for an enterprise product.In April 2023, Company inaugurated a stateoftheart Research Development (RD) Centre, named Adi Godrej Centre for Chemical Research and Development in Rabale, Maharashtra.
Read More

Astec Lifesciences FAQs

Astec Lifesciences share price is ₹729.35 in NSE and ₹736.9 in BSE as on 20/2/2025 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

Astec Lifesciences share price in the past 1-year return was -20.33. The Astec Lifesciences share hit a 1-year low of Rs. 647.5 and a 1-year high of Rs. 1474.4.

The market cap of Astec Lifesciences is Rs. 1430.36 Cr. as of 20/2/2025 12:00:00 AM.

The PE ratios of Astec Lifesciences is 0 as of 20/2/2025 12:00:00 AM.

The PB ratios of Astec Lifesciences is 4.96 as of 20/2/2025 12:00:00 AM

The Mutual Fund Shareholding in Astec Lifesciences was 4% at the end of 20/2/2025 12:00:00 AM.

You can easily buy Astec Lifesciences shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -